Key result
Increased 3D left ventricular end-systolic volume was associated with a 1.92-fold higher adjusted risk of the primary composite outcome in patients with primary mitral regurgitation.
Why the study?
Assessment of left ventricular dilatation using standard echocardiography in patients with mitral regurgitation often yields inconsistent results, motivating evaluation of 3D LV end-systolic volume for improved risk stratification.
Does increased 3D left ventricular end-systolic volume improve risk stratification and predict adverse outcomes in adults with significant mitral regurgitation?
Cohort (n=227)
Single-blind
No
Does increased 3D left ventricular end-systolic volume improve risk stratification and predict adverse outcomes in adults with significant mitral regurgitation?
Measuring 3D left ventricular end-systolic volume alongside standard 2D diameters identifies high-risk subgroups in significant mitral regurgitation, enhancing prognostic stratification for disease progression, heart failure, and death.
Answers are grounded in this paper and cite their sources.
May enhance risk stratification in primary MR; leaves open prospective validation versus 2D echocardiography.
Aims In the follow-up of patients with mitral regurgitation (MR), assessment of left ventricular (LV) dilatation using standard echocardiography often yields inconsistent results. We investigated whether measuring 3D LV end-systolic volume (3DLVESV) improves risk stratification in moderate or greater MR. Methods and results In the prospective 3D Echocardiography and Cardiovascular Prognosis in Mitral Regurgitation (3D-PRIME) study, 227 patients −142 with primary (PMR) and 85 secondary MR (SMR)- underwent 2D/3D echocardiography. 3DLVESV was increased if ≥41.5/35 mL/m², and LV end-systolic diameter (LVESD) enlarged if ≥39.8/34.8 mm in men/women. The primary outcome was a composite of MR progression towards intervention, death, or heart failure hospitalization (HFH). Death or HFH was a secondary outcome. At baseline, 28% of PMR and 54% of SMR patients had increased 3DLVESV. After 21 (15–25) months, increased 3DLVESV was associated with 1.9-fold (1.2–3.2) higher adjusted risk of the primary outcome in PMR, and 4.1-fold (1.6–10.7) higher risk of death or HFH in SMR (P < 0.05). 3DLVESV and LVESD concordantly identified LV dilatation in 20% of PMR patients and were discordant in 27%. Both patients with increased 3DLVESV only, and those with increased both 3DLVESV and LVESD, had high risk of the primary outcome after adjusting for recommendations for intervention in PMR: HR 7.1 (2.9–16.9) and 4.9 (2.1–11.1), respectively (P < 0.001). Conclusion Increased 3DLVESV is associated with a higher risk of adverse events in patients with significant MR. In PMR, evaluating LV dilatation using both 3DLVESV and LVESD may enhance risk stratification and aid in patient selection for close follow-up. ClinicalTrials.gov identifier NCT04442828, 17 April 2020.
No takes yet. Share an insight, caveat, or question.
Cramariuc et al. (2026) conducted a cohort in Significant mitral regurgitation (primary or secondary) (n=227). Increased 3D left ventricular end-systolic volume vs. Normal 3D left ventricular end-systolic volume was evaluated on Composite of MR progression towards intervention, death, or heart failure hospitalization in primary MR (HR 1.92, 95% CI 1.17-3.16, p=0.010). Increased 3D left ventricular end-systolic volume was associated with a 1.92-fold higher adjusted risk of the primary composite outcome in patients with primary mitral regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: